Clinical Trials Logo

Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to Non-Hodgkin's Lymphoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT00041730 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the ability of patients treated with Rituxan® plus FavId™ and GM-CSF to mount an immune response (humoral and/or cellular) to KLH and their idiotype.

NCT ID: NCT00022958 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Start date: September 1998
Phase: N/A
Study type: Interventional

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.

NCT ID: NCT00022932 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Start date: January 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of using Iodine-131 Anti-B1 Antibody for the treatment of patients with large B-cell non-Hodgkin's lymphoma (NHL) who have achieved a response following 6-8 cycles of CHOP therapy.

NCT ID: NCT00022906 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Start date: May 1999
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the proper dose, effectiveness, and safety of using Iodine-131 Anti-B1 Antibody for the treatment of patients with previously treated non-Hodgkin's lymphoma (NHL) who have greater than 25% bone marrow involvement with lymphoma.

NCT ID: NCT00022893 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkin's lymphoma (NHL) who previously responded (PR, CCR, or CR) for at least 3 months to Iodine-131 Anti-B1 Antibody therapy.